Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $7.75 to $8.
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $7.75 to $8.